Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Metadata
Title
Angiotensin-Receptor Blockers: Revival of the Systemic Prevention of Restenosis?
Author
Robert L. Wilensky
Publication date
01-01-2003
Publisher
Kluwer Academic Publishers
Published in
Cardiovascular Drugs and Therapy / Issue 1/2003
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1023/A:1024259909740

Other articles of this Issue 1/2003

Cardiovascular Drugs and Therapy 1/2003 Go to the issue

OriginalPaper

Exercise Intolerance During Post-MI Heart Failure in Rats: Prevention with Supplemental Dietary Propionyl-L-Carnitine

OriginalPaper

Reduction of Infarct Size by Short-Term Pretreatment with Atorvastatin

ReviewPaper

HDL-C and Triglyceride Levels: Relationship to Coronary Heart Disease and Treatment with Statins

ReviewPaper

Genetic Polymorphisms in Emerging Cardiovascular Risk Factors and Response to Statin Therapy

OriginalPaper

Drugs Modifying Nitric Oxide Metabolism Affect Plasma Cholesterol Levels, Coagulation Parameters, Blood Pressure Values and the Appearance of Plasma Myocardial Necrosis Markers in Rabbits: Opposite Effects of L-NAME and Nitroglycerine

Letter to the Editor

Effect of 17β-Estradiol on Soluble P-Selectin in Coronary Artery Bypass Grafting

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits